Eosinophilic granulomatosis with polyangiitis

What is Eosinophilic granulomatosis with polyangiitis?

Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome, is a rare autoimmune disorder that causes inflammation of blood vessels throughout the body. This ANCA-associated vasculitis primarily affects small to medium-sized blood vessels, leading to tissue damage in multiple organs. EGPA typically develops in adults with a history of asthma and allergies, and is characterized by elevated levels of eosinophils, a type of white blood cell. With an incidence of only 1-3 cases per million people annually, EGPA is considered an extremely rare disease that requires specialized medical care and ongoing management.

Key statistics

Symptoms

Primary symptoms: Severe asthma, chronic sinusitis, peripheral neuropathy, skin rashes, fatigue, weight loss, fever

EGPA typically progresses through three overlapping phases. The allergic phase usually begins in adulthood and includes severe asthma that may be difficult to control, allergic rhinitis, and nasal polyps. Patients often develop chronic sinusitis with recurrent infections.

The eosinophilic phase is characterized by extremely high levels of eosinophils in the blood and tissues. During this phase, patients may experience pneumonia-like symptoms, including cough, chest pain, and shortness of breath. Gastrointestinal symptoms such as abdominal pain, diarrhea, and bleeding may occur.

Submit Your Paper

The vasculitic phase involves inflammation of blood vessels and can affect multiple organ systems. Peripheral neuropathy is common, causing numbness, tingling, and weakness in hands and feet. Skin manifestations include purpura (purple spots), nodules, and ulcers. Cardiac involvement may include heart muscle inflammation, heart rhythm abnormalities, and heart failure. Kidney involvement, while less common than in other forms of vasculitis, can lead to glomerulonephritis and reduced kidney function.

Causes and risk factors

EGPA is classified as an ANCA-associated vasculitis, referring to anti-neutrophil cytoplasmic antibodies that are present in approximately 40% of patients. The exact cause remains unknown, but the condition is believed to result from a complex interaction between genetic predisposition, environmental triggers, and immune system dysfunction.

Risk factors include a personal history of asthma and allergic diseases, particularly adult-onset asthma that becomes increasingly severe. Some studies suggest that certain medications, including leukotriene receptor antagonists used to treat asthma, may unmask or trigger EGPA in susceptible individuals, though this relationship remains controversial. Environmental allergens and infections may also serve as triggers in genetically predisposed individuals.

Unlike many rare diseases, EGPA is not inherited in a simple genetic pattern, though some genetic variations may increase susceptibility to developing the condition.

Prevention

Currently, there are no established methods to prevent EGPA, as the underlying triggers and genetic factors are not fully understood. Since EGPA is not a hereditary condition in the traditional sense, genetic testing and carrier screening are not applicable.

However, early recognition and treatment of severe asthma and allergic symptoms may help prevent progression to the vasculitic phase. Patients with difficult-to-control asthma, especially when accompanied by chronic sinusitis and elevated eosinophil counts, should receive careful monitoring by healthcare providers familiar with EGPA.

Complications

Without proper treatment, EGPA can cause permanent organ damage and be life-threatening. Cardiac complications are the leading cause of death and may include cardiomyopathy, coronary artery disease, and heart rhythm disturbances. Peripheral neuropathy can result in permanent nerve damage, leading to chronic pain, weakness, and disability.

Pulmonary complications may include persistent asthma, lung infiltrates, and in rare cases, pulmonary fibrosis. Gastrointestinal bleeding and perforation can occur due to vasculitis affecting the digestive tract. Kidney involvement, while less frequent than in other ANCA-associated vasculitides, can progress to chronic kidney disease if left untreated.

Diagnosis

Diagnosing EGPA requires a combination of clinical criteria, laboratory tests, and imaging studies. The American College of Rheumatology criteria include: asthma, eosinophilia greater than 10%, neuropathy, pulmonary infiltrates, paranasal sinus abnormalities, and biopsy showing eosinophils in vessel walls or surrounding areas.

Laboratory tests include complete blood count showing eosinophilia (often >1,500 cells/μL), ANCA testing (positive in about 40% of patients, typically MPO-ANCA), elevated inflammatory markers (ESR, CRP), and assessment of organ function including kidney and liver tests.

Imaging studies may include chest X-rays or CT scans showing pulmonary infiltrates, sinus CT revealing chronic sinusitis, and echocardiography to assess cardiac involvement. MRI or CT angiography may be used to evaluate blood vessel inflammation.

Tissue biopsy from affected organs can provide definitive diagnosis, showing necrotizing vasculitis with eosinophilic infiltration. Common biopsy sites include skin, lung, or nerve tissue.

Treatment

Treatment of EGPA typically involves immunosuppressive therapy to control inflammation and prevent organ damage. Prednisone or other corticosteroids are the cornerstone of initial treatment, often providing rapid symptom relief and control of eosinophilia.

For severe cases or those requiring long-term treatment, additional immunosuppressive agents may be necessary, including methotrexate, azathioprine, or cyclophosphamide for organ-threatening disease.

Mepolizumab, a monoclonal antibody targeting interleukin-5, has been approved specifically for EGPA and represents a significant advancement in treatment. This therapy can help reduce corticosteroid dependence and control eosinophilia.

Rituximab may be considered for ANCA-positive patients or those with refractory disease. Supportive care includes management of asthma with bronchodilators and inhaled corticosteroids, treatment of neuropathy pain, and monitoring for cardiac complications.

Prognosis

With appropriate treatment, the prognosis for EGPA has improved significantly over recent decades. The 5-year survival rate exceeds 90% with current treatment approaches. However, the condition typically requires long-term management, and many patients experience disease flares that necessitate treatment adjustments.

Factors associated with more severe disease and poorer prognosis include cardiac involvement, kidney disease, gastrointestinal bleeding, and central nervous system involvement. Early diagnosis and treatment are crucial for preventing irreversible organ damage and optimizing long-term outcomes.

Many patients can achieve sustained remission and maintain good quality of life with appropriate therapy, though complete cure is rare and ongoing medical supervision is typically necessary.

Quality of life

Living with EGPA requires ongoing adaptation and self-management. Patients often need to modify their daily activities during active disease phases and may experience chronic symptoms such as neuropathy pain and persistent asthma.

Regular exercise, when tolerated, can help maintain cardiovascular health and manage steroid-related side effects such as bone loss and muscle weakness. A balanced diet rich in calcium and vitamin D is important for patients on long-term corticosteroids.

Sleep quality may be affected by breathing difficulties, pain, or medication side effects. Establishing good sleep hygiene and working with healthcare providers to manage symptoms can improve rest and recovery.

Mental health support is crucial, as living with a rare, chronic disease can lead to anxiety, depression, and feelings of isolation. Connecting with patient support groups and mental health professionals familiar with chronic illness can provide valuable coping strategies.

Many patients can continue working with appropriate accommodations, though some may need to modify their careers or consider disability benefits during severe flares or if permanent complications develop.

Pregnancy and fertility

EGPA can present unique challenges during pregnancy. The condition may improve, worsen, or remain stable during pregnancy, making careful monitoring essential. Some medications used to treat EGPA, particularly cyclophosphamide and methotrexate, are contraindicated during pregnancy and require switching to safer alternatives.

Prednisone is generally considered safe during pregnancy when necessary to control disease activity. Azathioprine may be used as a steroid-sparing agent when needed.

Preconception counseling with rheumatologists and maternal-fetal medicine specialists is recommended to optimize disease control and medication safety. Women should achieve stable remission before conception when possible.

Since EGPA is not typically inherited, genetic counseling for the condition itself is not usually necessary, though patients may benefit from discussing family planning with their healthcare team.

Children

EGPA is extremely rare in children, with most cases occurring in adults aged 40-60 years. When it does occur in pediatric patients, the presentation and treatment approach are generally similar to adults, though medication dosing must be adjusted for age and weight.

Children with EGPA require specialized care from pediatric rheumatologists or other specialists experienced in treating vasculitis in young patients. Growth and development must be carefully monitored, particularly when corticosteroids are used long-term.

When to see a doctor

Seek immediate medical attention for chest pain, severe breathing difficulties, signs of stroke or heart attack, severe abdominal pain with bleeding, or rapidly worsening weakness or numbness.

Schedule prompt medical evaluation for new or worsening asthma in adults, chronic sinusitis with nasal polyps, unexplained skin rashes or nodules, persistent numbness or tingling in hands or feet, or unexplained weight loss and fatigue.

Patients with diagnosed EGPA should maintain regular follow-up with their rheumatologist and report any new symptoms or medication side effects promptly.

Regional context

Limited data exists on EGPA prevalence specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) or broader Eastern Mediterranean area. The Global Medical Journal invites healthcare providers and researchers from these regions to contribute data on local EGPA prevalence, clinical presentations, and treatment outcomes to improve understanding of this rare disease across different populations and geographic areas.

Research and clinical trials

Current research focuses on understanding the underlying mechanisms of EGPA, developing targeted therapies, and improving long-term outcomes. Studies are investigating the role of specific immune pathways and genetic factors that contribute to disease development.

Clinical trials are exploring new biologic therapies, including agents targeting different inflammatory pathways beyond IL-5. Research into biomarkers that can predict disease flares or treatment response is ongoing.

Patients interested in clinical trials can search for opportunities at ClinicalTrials.gov using the terms “eosinophilic granulomatosis with polyangiitis” or “Churg-Strauss syndrome.” Participation in research studies can provide access to experimental treatments and contribute to advancing understanding of this rare condition.

Frequently asked questions

Is EGPA contagious or hereditary?

EGPA is neither contagious nor directly hereditary. It is an autoimmune condition that may have some genetic predisposition, but it cannot be passed from person to person or inherited in a simple genetic pattern.

Can EGPA be cured?

Currently, there is no cure for EGPA, but the condition can often be controlled with appropriate treatment. Many patients achieve long-term remission and live normal, active lives with proper medical management.

Will I need to take medications for life?

Most patients require some form of ongoing treatment to maintain remission and prevent disease flares. However, the intensity and type of treatment may change over time, and some patients may be able to reduce medications during stable periods.

How does EGPA affect life expectancy?

With current treatments, most people with EGPA have a normal or near-normal life expectancy. The 5-year survival rate exceeds 90%, and many patients live for decades after diagnosis with good quality of life.

Can I have children if I have EGPA?

Many women with EGPA can have successful pregnancies, though careful planning and monitoring with specialized healthcare providers is essential. Some medications may need to be adjusted before and during pregnancy.

Support and resources

• Vasculitis Foundation – Dedicated organization for vasculitis patients and families
• Orphanet – European reference portal for rare diseases
• National Organization for Rare Disorders (NORD) – Patient advocacy and information
• EURORDIS – European rare disease patient advocacy alliance
• World Health Organization Rare Diseases – Global health information and initiatives

Related conditions

• Granulomatosis with polyangiitis
• Microscopic polyangiitis
• Hypereosinophilic syndrome
• Polyarteritis nodosa
• Allergic bronchopulmonary aspergillosis

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.